{"analyses":[{"ciLowerLimit":"0.760","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.249","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4172","pValueComment":"Based on 1-sided test.","paramType":"Hazard Ratio (HR)","paramValue":"0.975","statisticalComment":"Analysis was stratified by the number of previous therapies (3 vs 4 vs ≥ 5) and geographical region (Europe vs. non-Europe)","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.7","upperLimit":"12.0","value":"10.0"},{"groupId":"OG001","lowerLimit":"8.4","upperLimit":"14.4","value":"10.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"Time elapsed between the randomization date and the date of death. Participants who were still alive were censored at date when the subject is last known alive or the data cutoff date, whichever occurs earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Best Supportive Care: Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).\n\nOptional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).","id":"OG000","title":"Best Supportive Care"},{"description":"Carfilzomib: 20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \\[Days 1, 2, 8, 9, 15, 16\\] for individual subjects).","id":"OG001","title":"Carfilzomib"}],"paramType":"MEDIAN","populationDescription":"The intent to treat (ITT) analysis set comprised all randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively.","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}